Among throat swabs processed in the microbiology laboratory as back-up for negative rapid antigen detection test results, we found a significant increase in the proportion that tested positive for group A streptococci after changing from throat culture to a molecular test.
Among throat swabs processed in the microbiology laboratory as back-up for negative rapid antigen detection test results, we found a significant increase in the proportion that tested positive for group A streptococci after changing from throat culture to a molecular test.
For group A streptococcus testing, our hospital laboratory replaced throat cultures with a stand-alone molecular diagnostic test that takes no more than 1 hour to perform. The prevalence of positive laboratory test results increased significantly (P < .0001) after the change to molecular testing, probably because of the extreme sensitivity of the molecular test.
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Pharyngeal infection caused by group A Streptococcus (GAS) puts patients at risk for acute rheumatic fever (ARF) and other complications. Accurate diagnosis of GAS pharyngitis and prompt antibiotic treatment are the hallmarks of ARF prevention. A throat swab cultured on a sheep blood agar plate (BAP) has been considered the gold standard for diagnosis in children since Breese and Disney [1] pioneered its use more than 60 years ago. Throat cultures take 18 to 48 hours to provide a definitive result. The rapid antigen detection test (RADT), which takes 5 to 15 minutes to provide a result, began to supplant office throat culture as the first-line test for GAS in the 1980s [2] . RADTs are quite specific, but they have relatively poor sensitivity (83%-88% in a 2016 Cochrane review [3] ). Thus, management guidelines in the United States recommend the use of a back-up throat culture to confirm negative RADT results in children [4, 5] .
Extremely sensitive and specific nucleic acid amplification tests for detecting GAS in a short time have become available. These molecular tests provide a definitive result (GAS positive or negative) in much less time than the 18 to 48 hours needed for culture. The illumigene assay (Meridian Bioscience, Cincinnati, Ohio) amplifies and detects the highly conserved speB gene of GAS. It requires approximately 1 hour to perform, and it was cleared by the US Food and Drug Administration as a standalone test for GAS pharyngitis. In 3 hospital laboratory studies, both the sensitivity and specificity of this test were >95% when compared to culture [6] [7] [8] .
In the winter of 2012/2013, the microbiology laboratory of the Ann & Robert H. Lurie Children's Hospital of Chicago (288 beds, approximately 56 000 emergency department [ED] visits per year) compared the illumigene test to BAP throat culture in a prospective study of patients with pharyngitis [7] . Afterward, in mid-March 2014, the laboratory replaced throat culture with the illumigene test for diagnosing GAS pharyngitis. Thus, illumigene is now used whenever the result of an RADT in the ED is negative. The median turnaround time for illumigene in a laboratory quality review in the summer of 2014 was 1.5 hours (range, 53 minutes to 14.7 hours; 171 ED patients). We then performed a retrospective review of hospital records to assess the effect of this change in technology on the frequency of diagnosis of GAS pharyngitis among RADT-negative ED patients.
METHODS
We used the hospital electronic medical record to identify ED patients who were tested in the laboratory for GAS pharyngitis. We assessed laboratory results from April through September 2014, the first 6 full months of molecular testing, and the same months in 2015. For comparison, we assessed records from April through September 2012 and 2013, a time at which throat cultures were used. April through September is typically a relatively low-prevalence time of year for GAS pharyngitis in Chicago. The data we used came from an electronic medical record order entry and result review; no personal health information and no demographic or clinical data were obtained. This study was determined to be exempt from review by the Ann & Robert H. Lurie Children's Hospital Institutional Review Board.
When GAS pharyngitis is suspected in the ED, a clinician swabs the patient's throat with 2 swabs simultaneously using e146 • JPIDS 2018:7 (September) • BRIEF REPORT a double-swab system that includes liquid Stuart transport medium (Copan Diagnostics, Inc., Murrieta, California). One swab is used for the RADT in the ED as the initial test for GAS pharyngitis. When the RADT result is positive, the second swab is discarded. In all years of this study, the same RADT (Quidel QuickView Dipstick Strep A, Quidel Corporation, San Diego, California) was used. In 2012 and 2013, when the RADT result was negative, the second throat swab was sent in its transport medium to the microbiology laboratory for standard GAS culture on 5% sheep blood agar. GAS identification in the laboratory was based on colony morphology, Gram staining, catalase test result, and serogrouping using PathoDX Strep grouping (Remel, Lenexa, Kansas). Culture results were reported as negative if no growth of GAS was seen after 48 hours of incubation. The laboratory did not routinely report the growth of streptococci other than those of group A.
Beginning in mid-March 2014, the illumigene test replaced BAP culture for testing all ED throat swabs sent to the laboratory for back-up GAS testing when the RADT result is negative. The illumigene test uses loop-mediated isothermal amplification of the GAS target sequence, speB. The process time from preparation to result is approximately 1 hour using the manufacturer's proprietary test kits and countertop device. An internal control indicates if the test is successful; positive and negative controls are run on each new test lot before patient testing and again every 30 days. The test was performed by trained laboratory technologists following the manufacturer's instructions [6] [7] [8] . χ 2 statistics were used for data analysis. Table 1 
RESULTS

DISCUSSION
The data show that among RADT-negative ED patients, an extremely significant increase occurred in the proportion of back-up GAS test results that were positive after our laboratory replaced the time-honored BAP culture with a new standalone highly sensitive and specific molecular test. Positive GAS test rates in studies of children with clinical pharyngitis, including 2 studies of the illumigene test, generally range from approximately 20% to 30% [3, 6, 7, 9] . All swabs in our study were from RADT-negative ED patients, so it is difficult to compare our results directly to data from most studies of GAS pharyngitis. Although in the United States RADTs are considered too insensitive to be used without back-up testing in children when the results are negative [2] [3] [4] [5] , they nevertheless identify most patients who harbor GAS in the pharynx. As a result, most swabs in this study that would have tested positive by BAP culture or molecular test were never sent to the laboratory because the RADT result was positive. Therefore, our results do not represent the true prevalence of GAS pharyngitis. We unfortunately do not know how many patients had a positive RADT result.
Why did the prevalence of positive tests increase with illumigene? There is a spectrum effect with both RADTs and BAP cultures; patients with symptoms more consistent with GAS pharyngitis (higher pretest probability) are more likely to have a positive test result [9] . Some evidence indicates that the illumigene test does not behave in this way; in a small study that used the McIsaac score [10] as a measure of clinical pretest probability, those with a low or high pretest probability of GAS pharyngitis were equally likely to have a positive illumigene test result (McIsaac score ≤ 2, 100% of patients; McIsaac score ≥ 3, 98% of patients) [8] . This result was markedly different from RADT and throat culture results in the same study. The absence of spectrum effect, if confirmed, is likely related to the ability of this and other molecular tests to identify GAS when only a small amount of the target gene sequence is available to be amplified, as might occur when very few GAS organisms are present on a swab.
The RADT used in our ED was the same in all study years, and the clinical management protocol in the ED did not change during the periods we studied (see Methods). There is no reason to suspect that changes in RADT sensitivity or clinical management affected our results. We do not suspect that a significant change in the prevalence of symptomatic pharyngitis or bonafide streptococcal pharyngitis occurred in Chicago after 2012; only a dramatic persistent or recurrent increase in the prevalence of bona-fide GAS pharyngitis would account for our results. We unfortunately have no data regarding disease prevalence in any of the time periods included in this study.
We also have no information about the clinical status of the patients whose throat swabs were tested or the clinical decision-making of the clinicians involved in their care. As part of a teaching hospital with a large pediatric residency training program, our ED is staffed by numerous resident and attending physicians, medical students, and advanced practice nurses, and frequent changes in staffing occur that affect overall clinical acumen and medical decision-making in ways that are unmeasurable. However, it is unlikely that the turnover in ED clinicians would systematically lower the culture-positive rates or increase the illumigene-positive rates of throat swabs. Studies have found that few false-positive illumigene results occur; that is, if the test is positive, GAS are almost always detected by culture (speB is not present in streptococcal species other than Streptococcus pyogenes). When polymerase chain reaction (PCR) is used to adjudicate discrepant culture and molecular results (ie, illumigene positive, culture negative), the PCR result is usually positive [8] [9] [10] . The clinical importance of the increased sensitivity of this test (compared to BAP culture) remains to be determined in areas with a low prevalence of ARF and other GAS sequelae, such as the United States, Canada, and western Europe. The high sensitivity of molecular tests could lead to the treatment of more patients with pharyngitis and lower rates of ARF. Moreover, more patients might be classified as having ARF than were in the past; the diagnosis of ARF requires evidence of an antecedent GAS infection, evidence that might be found more readily by molecular testing than by traditional throat culture. In this study, we did not establish that the molecular test is more likely than culture to identify GAS carriers who have an intercurrent illness that is not actually caused by GAS. Studies are underway to evaluate that possibility, establish limits of detection for the illumigene test, and assess the presence or absence of a symptom-related spectrum effect.
CONCLUSIONS
The results of this retrospective laboratory study raise the possibility that molecular tests for GAS are associated with substantially higher rates of identification of patients as being GAS positive and, thus, likely associated with increased antibiotic prescribing. This might not represent a benefit to patients, especially in areas with low rates of ARF.
The speed, greater sensitivity, and greater specificity of newer molecular tests for GAS will likely make their use increasingly common. As with multiplex molecular respiratory viral panels, it might be difficult to interpret the results if testing is performed indiscriminately [11, 12] . Our findings provide strong support for carefully selecting patients for GAS testing and specifically excluding those with overt viral symptoms, as recommended in the guidelines from the Infectious Diseases Society of America and other groups [4, 5, 9] .
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